Ep 52: knownwell CMO Dr. Angela Fitch on The Future of GLP-1s and New Approaches to Obesity Medicine
Nov 14, 2024
auto_awesome
Dr. Angela Fitch, Founder and CMO of knownwell, shares her expertise on obesity medicine, emphasizing the need for innovative care. She discusses the transformative potential of GLP-1 medications, highlighting their impact beyond obesity treatment to conditions like Alzheimer’s. The conversation also addresses challenges in insurance coverage and the importance of continuous and integrated care. Dr. Fitch advocates for recognizing obesity as a serious medical condition and stresses the necessity of creating a supportive environment for effective treatment.
Dr. Angela Fitch highlights the transformative potential of GLP-1 medications in reshaping obesity treatment but warns of accessibility challenges.
The establishment of knownwell aims to provide inclusive and integrated care for obesity by addressing systemic stigma and fragmentation in healthcare.
Deep dives
Current Standards of Care in Obesity Medicine
The evolving landscape of obesity medicine is marked by the push to develop comprehensive standards of care, which have been notably absent. Dr. Angela Fitch emphasizes that the increasing availability of effective medications, particularly GLP-1 agonists, is reshaping perceptions and practices in the treatment of obesity. However, the stigma surrounding obesity continues to hinder patients from seeking proper care, often leading them to alternative, less coordinated approaches. There is a critical need for unified guidelines and a collaborative care model that facilitates better access and understanding of obesity as a complex disease.
The Formation of KnownWell
KnownWell was established to address the gap in effective obesity treatment by providing weight-inclusive primary care. Dr. Fitch’s journey from primary care to obesity medicine laid the foundation for creating a model that integrates metabolic health care directly into patients' medical homes. Frustrated by the fragmented healthcare system and the stigma faced by those with obesity, she partnered with Brooke Bajorski-Pratt to develop a clinic that supports patients without judgment or barriers. The goal is to streamline care, allowing patients to receive comprehensive treatment without having to navigate multiple healthcare providers.
Challenges and Future of GLP-1 Medications
The use and research surrounding GLP-1 medications have progressed significantly, with Dr. Fitch highlighting their efficacy in addressing obesity and their emergence as essential tools in this field. While initial uptake was met with excitement, recent influxes in interest have introduced challenges regarding accessibility and coverage. The financial burden of these medications remains a concern, as many patients lack adequate insurance coverage for obesity treatment. As research continues to uncover benefits associated with these drugs, such as reductions in cardiovascular risks, the healthcare system must adapt to ensure broader access and sustainable treatment pathways.
The Need for Comprehensive Long-term Care
Dr. Fitch points out the importance of treating obesity as a chronic disease that requires ongoing management rather than a one-time intervention. This perspective necessitates the integration of supportive services—such as dietitians and health coaches—into patients’ care to ensure sustained success with weight management. The existing approach often sees patients experiencing weight regain once they discontinue medication, underscoring the necessity for a structured, long-term care strategy. Building a healthcare system that supports continuous treatment and helps patients maintain their progress is vital for improving overall health outcomes.
Jacob sits down with Dr. Angela Fitch, the Founder and CMO of knownwell. knownwell has raised $25 million from investors like a16z and Flare Capital Partners to provide weight-inclusive primary care and metabolic health care. They discuss the future of obesity care, where we are with GLP-1s, the need to expand coverage, and more.